A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Adults

Project: Research project

Project Details

StatusActive
Effective start/end date10/30/24 → 10/29/29

Funding

  • Merck Sharp and Cohme Corporation ( Award # ): $15,500.00